BioTheryX, Inc.

Protein-degradation specialist BioTheryX, Inc. has landed its first partnership, unveiling an alliance with Incyte Corporation on 5 April under which it will deploy its PRODEGY platform technology

Venture capital mega-rounds of $100m or more are driving record levels of VC investment in biopharmaceutical companies, and these big financings have not taken a summer break. [Sidebar#SC144714] The l

Private biopharmaceutical companies raised more than $1bn from venture capital, seed financing and government investments during the past week, including Eliem Therapeutics, Inc. , which said on 24 M

Former Gilead Sciences, Inc. research and development leader Norbert Bischofberger joined Kronos Bio, Inc. in 2018 as CEO and an investor to develop novel cancer drugs, but has brought additional